National Institutes of Health
By
National Institutes of Health
Published: Dec. 7, 2023, 8:09 p.m.·
Tags:
Extrapulmonary TB,
Scientific research
A trial of a new drug regimen to treat tuberculous meningitis (TBM) has started enrolling adults and adolescents in several countries where tuberculosis (TB) is prevalent. The Improved Management with Antimicrobial Agents Isoniazid Rifampicin Linezolid for TBM (IMAGINE-TBM) trial will compare a six-month regimen of four drugs with the nine-month, standard-of-care regimen for TBM. The study aims to generate evidence that could improve treatment for people with TBM. IMAGINE-TBM is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and implemented through the NIAID-funded Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG).
Read More →
By
National Institutes of Health
Published: July 5, 2023, 4:02 p.m.·
Tags:
Treatment
The first clinical trial of a three-month TB treatment regimen is closing enrollment because of a high rate of unfavorable outcomes with the investigational course of treatment.
Read More →
By
National Institutes of Health
Published: March 7, 2023, 5:06 p.m.·
Tags:
Vaccines,
Scientific research
A clinical trial testing a freeze-dried, temperature-stable experimental tuberculosis (TB) vaccine in healthy adults found that it was safe and stimulated both antibodies and responses from the cellular arm of the immune system. The Phase 1 trial was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. A non-temperature stable form of the candidate previously had been tested in several clinical trials. However, this was the first clinical trial of any subunit TB vaccine candidate in a temperature-stable (thermostable) form. Results are published in Nature Communications.
Read More →
By
National Institutes of Health
Published: July 26, 2021, 3:04 p.m.·
Tags:
HIV coinfection,
Scientific research
The National Institutes of Health (NIH) has renewed grants to seven regional centers that compose the International epidemiology Databases to Evaluate AIDS (IeDEA), awarding $20.8 million in first-year funding. The 15-year-old IeDEA program efficiently advances knowledge about HIV by pooling and analyzing de-identified health data from more than two million people with HIV on five continents to answer research questions that individual studies cannot address. The grants are expected to last five years and to total an estimated $100 million.
Read More →
By
National Institutes of Health
Published: Feb. 11, 2020, 8:57 p.m.·
Tags:
Scientific research
In September 2018, the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, issued its Strategic Plan for Tuberculosis Research, which outlined research priorities to reduce and ultimately end the burden of tuberculosis (TB). TB is a bacterial disease that has claimed the lives of more than a billion people in the past two centuries. Now, a new “Perspective” in The Journal of Infectious Diseases by NIAID Director Anthony S. Fauci, M.D., and other Institute officials summarizes recent progress in improved TB diagnostics, therapeutic regimens and prevention approaches that made 2019 a “banner year” for TB research.
Read More →
By
National Institutes of Health
Published: Jan. 2, 2020, 12:07 a.m.·
Tags:
Vaccines
Tuberculosis (TB), an ancient disease, is the leading infectious cause of death globally, yet the world’s only licensed TB vaccine, Bacille Calmette-Guerin (BCG), was developed a century ago. Given to infants via a needle placed just under the skin, BCG protects babies from a form of the disease called disseminated TB but is far less effective at preventing pulmonary TB, the major cause of illness and deaths, in teens or adults.
Read More →
By
National Institutes of Health
Published: Oct. 2, 2019, 12:44 p.m.·
Tags:
HIV coinfection,
Prevention
October 2, 2019: Study results published today help clarify how to safely prevent tuberculosis (TB) in women living with HIV who are pregnant or have recently given birth, are taking antiretroviral therapy, and live where TB is highly prevalent.
Read More →
By
National Institutes of Health
Published: Sept. 29, 2019, 1:13 p.m.·
Tags:
Scientific research,
Vaccines
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded $30 million in first-year funding to establish new centers for immunology research to accelerate progress in tuberculosis (TB) vaccine development.
Read More →
By
National Institutes of Health
Published: June 26, 2019, 8:46 a.m.·
Tags:
Drug-resistant TB,
Prevention
A large clinical trial to assess treatments for preventing people at high risk from developing multidrug-resistant tuberculosis (MDR-TB) has begun. The study is comparing the safety and efficacy of a new MDR-TB drug, delamanid, with the decades-old TB drug isoniazid for preventing active MDR-TB disease in children, adolescents and adults at high risk who are exposed to adult household members with MDR-TB. Study participants are at high risk for MDR-TB because they either have latent TB infection, immune systems suppressed by HIV or other factors, or are younger than age 5 years and therefore have a weak immune system.
Read More →
By
National Institutes of Health
Published: March 8, 2019, 1:38 a.m.·
Tags:
HIV coinfection
Among people with HIV in Latin America, those diagnosed with tuberculosis (TB) at an initial clinic visit were about twice as likely to die within 10 years as people not initially diagnosed with TB, according to findings from a large observational study. This increased risk persisted despite the availability of TB treatment and mirrored patterns seen previously in HIV-negative populations, according to research supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Investigators from the NIAID-supported Caribbean, Central and South America Network for HIV Epidemiology (CCASAnet) presented the findings today at the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.
Read More →
Page 1 of 2 · Total posts: 10
1
2
Last→